Clinical Scorecard: Psoriasis Biologics Face Off in Drug Survival Study
At a Glance
| Category | Detail |
|---|---|
| Condition | Psoriasis |
| Key Mechanisms | Biologics targeting specific pathways in the immune system. |
| Target Population | Adult patients with psoriasis, both bionaive and bioexperienced. |
| Care Setting | Routine clinical practice, evaluated through the DERMBIO registry. |
Key Highlights
- Ustekinumab shows higher drug survival than adalimumab and secukinumab in bionaive patients.
- Bimekizumab, guselkumab, and risankizumab demonstrate the highest 2-year drug survival in bioexperienced patients.
- Standardized risk of treatment discontinuation at 5 years is lowest with ustekinumab (37%).
- 1-year drug survival is lower in bioexperienced patients compared to bionaive patients for several agents.
Guideline-Based Recommendations
Diagnosis
- Evaluate psoriasis severity and comorbidities, including psoriatic arthritis.
Management
- Consider biologic therapy based on previous treatment exposure and drug survival data.
Monitoring & Follow-up
- Regularly assess treatment persistence and patient response to therapy.
Risks
- Monitor for potential discontinuation rates associated with different biologics.
Patient & Prescribing Data
4,438 patients with psoriasis, 23% with comorbid psoriatic arthritis.
Bimekizumab, guselkumab, and risankizumab are preferred for bioexperienced patients due to higher drug survival.
Clinical Best Practices
- Utilize data from the DERMBIO registry to inform treatment decisions.
- Tailor biologic therapy based on patient history of biologic exposure.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
